论文部分内容阅读
关于改善抗葡萄球菌、链球菌和厌氧菌活性氟喹诺酮类的合成仍在继续。目前大多数有价值氟喹诺酮具有抗葡萄球菌作用,但其MICs常与推荐转效点浓度相关。然而,通常氟喹诺酮对链球菌抗菌活性弱,且不能抑制厌氧菌的生长。作者测定了WIN57273[1—环丙基—7—(2,6—二甲基—4—吡啶基)—6—氟—1,4—二氢—4—氧—3—喹诺酮羧酸]对各种临床分离菌的体外抗菌活性,并与其它氟喹诺酮和2个扩谱β—内酰胺进行了比较。
The synthesis of fluoroquinolones to improve anti-staphylococcal, streptococcal and anaerobic activity continues. Currently, most valuable fluoroquinolones have anti-staphylococcal activity, but their MICs are often associated with the recommended point-of-action concentration. However, fluoroquinolones are generally weak antibacterial activity against streptococci, and can not inhibit the growth of anaerobic bacteria. The authors determined that WIN57273 [1-cyclopropyl-7- (2,6-dimethyl-4-pyridyl) -6- fluoro-1,4-dihydro-4-oxo-3-quinolonecarboxylic acid] In vitro antibacterial activity of various clinical isolates was compared with that of other fluoroquinolones and two spread spectrum β-lactams.